Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?

참고문헌 (9)

1. 박지혜, "Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis", Gut and Liver, 11(6), pp.828~834 (2017), 거트앤리버 발행위원회
2. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
3. Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
4. Han Y, "The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis", Int Immunopharmacol, 42, pp.168~175 (2017)
5. Shin JH, "Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents", Medicine (Baltimore), 95, pp.e2400~ (2016)
6. Liaw YF, "Tenofovir disoproxil fumarate (TDF), emtricitabine", TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, 2011, pp.53, 62~72
7. Hung CH, "Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation", Antimicrob Agents Chemother, 59, pp.3168~3173 (2015)
8. Cholongitas E, "The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis", Ann Gastroenterol, 28, pp.109~117 (2015)
9. López Centeno B, "Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B", Farm Hosp, 40, pp.279~286 (2016)

관련 논문AI추천